CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
| Заболевание | Acute Lymphoblastic Leukemia |
|---|---|
| Фаза | Фаза 2 |
| Спонсор | M.D. Anderson Cancer Center |
| Статус | Завершено |
| Участники | 90 участн. |
| Вмешательство | CMC-544 (Inotuzumab Ozogamycin), Rituximab |
| Дата начала | 4.06.2010 |
| Дата завершения | 18.04.2018 |
| Публикация результатов | 22.05.2019 |
Кратко
The goal of this clinical research study is to learn if CMC-544 given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied.
Number of Patients With Response
| Period 1: CMC-544 (Inotuzumab Ozogamycin) 1.3mg/m^2 | 3 Participants |
|---|---|
| Period 2: CMC-544 (Inotuzumab Ozogamycin) 1.8mg/m^2 | 25 Participants |
| Period 3: Weekly CMC-544 (Inotuzumab Ozogamycin) | 24 Participants |
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diag — National Cancer Institute (NCI)
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Tr — National Cancer Institute (NCI)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibruti — National Cancer Institute (NCI)
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituxim — National Cancer Institute (NCI)
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual — National Cancer Institute (NCI)
- Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute — Wake Forest University Health Sciences